Siftome Phase 3L

GSE272510

Lysine metabolism reprogramming reshapes the immune microenvironment and induces immunotherapy tolerance in liver cancer

Not suitable Dataset does not meet the current suitability threshold.
Sample grouping CSV Contrast CSV DESeq2 metadata CSV R handoff notes Handoff report Download instructions Open GEO dataset
Source
GEO
Search intent
Patient tissue tumor-vs-normal
Intent behavior
search-intent-behavior-v1
Submission date
2024-07-18
Last update
2025-12-02
Organization
Xi'an Jiaotong University
Department
Not available
Public date
2025-12-02
Experiment types
Expression profiling by high throughput sequencing
Platforms
GPL20795 HiSeq X Ten (Homo sapiens)
Series type
Series
SubSeries
Not available
BioProject
PRJNA1137233
Supplementary files
CSV: GSE272510_gene_count_matrix.csv.gz
Organism
Homo sapiens
Assay
bulk RNA-seq
Samples
6
Study design
Tumor vs unmatched normal
Specimen/source
Tissue
Scoring version
intent-aware-scoring-v15
Ranking batch
b69568dd1e4fe1b9ee2d880bf5495d748a7e4c5c11e4107f02528c3be0e76012
Ranking created
2026-06-05T20:20:27.088676Z
Warning version
intent-aware-warnings-v2

Current Intent Interpretation

Patient tissue tumor-vs-normal

Expectations

Organism
Homo sapiens
Assay
bulk RNA-seq
Specimen/source
patient tissue or biopsy
Controls
matched normal, adjacent normal, paired normal, healthy tissue control, or otherwise normal tissue control

Rules

Default filters
Human only; Bulk RNA-seq only; Tumor-normal only; Tissue or biopsy only; Hide biofluid/model systems
Warning rules
missing or unclear control group, unclear disease context, unclear tissue source, mixed sample types, model-system markers, secondary assay context, missing processed data, or small cohort size
Score caps
non-human datasets stay below the primary recommendation band, missing colorectal/colon/rectal/CRC context stays below the primary recommendation band, biofluid and model-system datasets cannot reach Recommended by default, microarray and secondary assays are capped unless explicitly enabled, or small cohorts are capped below high-confidence recommendations
Downgraded contexts
microarray unless explicitly enabled, biofluid-only datasets, cell-line datasets, organoid datasets, xenograft or PDX datasets, non-colorectal disease contexts, or treatment-only experiments

Study Classification

Tumor vs unmatched normal Tissue

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Review the sample grouping CSV and contrast CSV before running differential expression.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Still scan the grouping table for biology-specific ambiguity.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source links preserved

Ready

The dataset and sample accessions can be linked back to GEO.

Keep GEO dataset and sample links with exported metadata.

Bioinformatician Review

Standard analyst review

Proceed only after the analyst confirms grouping, exclusions, and source files.

No expert-review triggers were detected by Siftome.

Why This Is Ranked Here

Patient tissue tumor-vs-normal
Not suitable Dataset does not meet the current suitability threshold.

Score Components

  • relevance 60% Organism normalized. Assay type normalized. Tissue metadata normalized.
  • comparison suitability 0% Tumor and normal sample groups detected. No excluded sample type flags detected. Tumor/normal design boosted for colorectal tumor-vs-normal tissue triage. Patient tissue or biopsy specimens boosted for tissue comparison triage. Non-colorectal cancer context downgraded for colorectal tumor-vs-normal tissue ranking.
  • metadata quality 85% Sample source clarity: All samples have source metadata and clear GSE/GSM accessions. Group clarity: Rule-based grouping found both case and control samples. Disease clarity: Disease or condition metadata was not normalized. Tissue clarity: Tissue metadata normalized. Treatment clarity: No unclear treatment split detected in the sample metadata. Replicate clarity: No pooled sample or technical replicate flags detected. Data availability clarity: Dataset-level processed or raw data availability is explicit.
  • data availability 100% Processed data available. Raw data available.
  • overall 34% Weighted score: 30% relevance, 30% comparison suitability, 25% metadata quality, 15% data availability. Overall score capped because comparison suitability is weak for the selected search intent. Overall score capped because fewer than ten samples limit cohort confidence. Overall score capped because tumor/normal grouping is from a non-colorectal cancer context.

Derived Classifications

  • Organism Homo sapiens Organism remains rule-derived: Homo sapiens.
  • Assay bulk RNA-seq Assay remains rule-derived: bulk RNA-seq.
  • Study design Tumor vs unmatched normal Study design remains rule-derived: Tumor vs unmatched normal.
  • Specimen/source Tissue Specimen/source remains rule-derived: Tissue.
  • Likely case group tumor sample 3 samples
  • Likely control group normal tissue 3 samples

Warnings

  • DISEASE_LABEL_UNCLEAR warning Disease or condition label could not be normalized.

Intent Interpretation

  • Active intent Patient tissue tumor-vs-normal Ranks human colorectal tissue or biopsy cohorts where tumor samples can be compared with normal controls.
  • Organism expectation Homo sapiens Dataset organism is interpreted as Homo sapiens.
  • Assay expectation bulk RNA-seq Dataset assay is interpreted as bulk RNA-seq.
  • Specimen assumption patient tissue or biopsy Derived specimen/source is Tissue.
  • Control-group assumption matched normal, adjacent normal, paired normal, healthy tissue control, or otherwise normal tissue control Derived study design is Tumor vs unmatched normal; likely groups are tumor sample vs normal tissue.
  • Score caps Applied when matching conditions are present non-human datasets stay below the primary recommendation band, missing colorectal/colon/rectal/CRC context stays below the primary recommendation band, biofluid and model-system datasets cannot reach Recommended by default, microarray and secondary assays are capped unless explicitly enabled, or small cohorts are capped below high-confidence recommendations
  • Warning rules 1 active warning missing or unclear control group, unclear disease context, unclear tissue source, mixed sample types, model-system markers, secondary assay context, missing processed data, or small cohort size
  • Downgrade or exclusion reason Downgraded disease context: not a colorectal/GI cancer cohort. Derived from current-intent ranking reasons and warnings.

Applied Review Decisions

No active review decisions affect this ranking.

Ranking Facts

  • Recommendation Not suitable Dataset does not meet the current suitability threshold.
  • Supporting fact Tumor vs unmatched normal · Tissue · suitability 0%. Contributed to match or upgrade evidence.
  • Supporting fact Prioritized assay: bulk RNA-seq is the active assay expectation. Contributed to match or upgrade evidence.
  • Supporting fact Downgraded disease context: not a colorectal/GI cancer cohort. Contributed to match or upgrade evidence.
  • Supporting fact Processed data is available for downstream review. Contributed to match or upgrade evidence.
  • Supporting fact 1 warning require review. Contributed to match or upgrade evidence.
  • Caution fact Disease or condition label could not be normalized. Contributed to downgrade or manual-review evidence.
  • Caution fact Non-colorectal cancer context downgraded for colorectal tumor-vs-normal tissue ranking. Contributed to downgrade or manual-review evidence.
  • Caution fact Missing or unclear metadata: Disease clarity: Disease or condition metadata was not normalized. Contributed to downgrade or manual-review evidence.
  • Caution fact Missing or unclear metadata: Treatment clarity: No unclear treatment split detected in the sample metadata. Contributed to downgrade or manual-review evidence.
  • Caution fact Overall score capped because comparison suitability is weak for the selected search intent. Contributed to downgrade or manual-review evidence.
  • Caution fact Overall score capped because fewer than ten samples limit cohort confidence. Contributed to downgrade or manual-review evidence.
  • Caution fact Overall score capped because tumor/normal grouping is from a non-colorectal cancer context. Contributed to downgrade or manual-review evidence.
  • Caution fact Downgraded disease context: not a colorectal/GI cancer cohort. Contributed to downgrade or manual-review evidence.
  • Caution fact Comparison suitability score is below the Phase 1 recommended threshold. Contributed to downgrade or manual-review evidence.

Manual Corrections

0 active

Source Evidence

4 sources

GEO

Primary source

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Dataset accession
GSE272510
Sample records
6 GSM samples
  • GEO has priority for original metadata under the Phase 3J source rules.
  • Processed data: available.
  • Raw data: available.
  • No external source conflict is present in the current runtime data.

recount3

Not imported

Planned trusted source for processed count availability.

GEO accession
GSE272510
  • No recount3 project identifier has been imported for this dataset.
  • Once imported, recount3 has priority for processed count availability.
  • The recount3 source filter excludes this dataset until that linkage exists.
No recount3 sync data available.

Expression Atlas

Not imported

Planned source for curated expression experiment links.

GEO accession
GSE272510
  • No Expression Atlas experiment identifier has been imported for this dataset.
  • Once imported, Expression Atlas has priority for curated expression experiment links.
  • The Expression Atlas source filter excludes this dataset until that linkage exists.
No Expression Atlas sync data available.

PubMed

Unavailable

Publication context when PubMed identifiers are already known.

GEO accession
GSE272510
  • No PubMed identifier is present in the current runtime metadata.
  • No live PubMed search is performed from the dataset detail page.
No publication identifier imported.

Dataset Feedback

0 stored

Original GEO Metadata

dataset_accession: GSE272510
dataset_title: Lysine metabolism reprogramming reshapes the immune microenvironment and induces immunotherapy tolerance in liver cancer
organism: Homo sapiens
assay_type: bulk RNA-seq
processed_data_available: true
raw_data_available: true
submission_date: 2024-07-18
last_update_date: 2025-12-02
organization_name: Xi'an Jiaotong University
department: Not available
public_date: 2025-12-02
experiment_types: Expression profiling by high throughput sequencing
platforms: GPL20795 HiSeq X Ten (Homo sapiens)
sub_series: Not available
bioproject: PRJNA1137233
supplementary_files: CSV: GSE272510_gene_count_matrix.csv.gz
series_type: Series

Why It Matched

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.

Why It May Not Be Suitable

  • Disease or condition label could not be normalized.
  • Non-colorectal cancer context downgraded for colorectal tumor-vs-normal tissue ranking.
  • Missing or unclear metadata: Disease clarity: Disease or condition metadata was not normalized.
  • Missing or unclear metadata: Treatment clarity: No unclear treatment split detected in the sample metadata.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because fewer than ten samples limit cohort confidence.
  • Overall score capped because tumor/normal grouping is from a non-colorectal cancer context.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Warnings

  • warning DISEASE_LABEL_UNCLEAR Disease or condition label could not be normalized.

Normalized Fields

18 fields
Field Value Source Origin Confidence Evidence Reason
assay_type bulk RNA-seq dataset GSE272510 Runtime Siftome inference GEO:dataset:GSE272510:760500fbe3fd44e7d03540e5a4fc03207e3856d5d48a0054901b3ce96c2eb61a high confidence bulk rna-seq dataset_accession: GSE272510 dataset_title: Lysine metabolism reprogramming reshapes the immune microenvironment and induces immunotherapy tolerance in liver cancer organism: Ho... keyword match keyword match: bulk rna-seq
organism Homo sapiens dataset GSE272510 Runtime Siftome inference GEO:dataset:GSE272510:760500fbe3fd44e7d03540e5a4fc03207e3856d5d48a0054901b3ce96c2eb61a high confidence homo sapiens dataset_accession: GSE272510 dataset_title: Lysine metabolism reprogramming reshapes the immune microenvironment and induces immunotherapy tolerance in liver cancer organism: Ho... keyword match keyword match: homo sapiens
sample_type normal tissue sample GSM8403745 Runtime Siftome inference GEO:sample:GSM8403745:a2f083756095988b897f3e90d18ad229b19108e2dbf4eff46cc08e9dbf246653 low confidence normal sample_accession: GSM8403745 sample_title: MN-1,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary sample type match: normal
sample_type tumor sample sample GSM8403745 Runtime Siftome inference GEO:sample:GSM8403745:a2f083756095988b897f3e90d18ad229b19108e2dbf4eff46cc08e9dbf246653 low confidence tumor sample_accession: GSM8403745 sample_title: MN-1,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary sample type match: tumor
sample_type normal tissue sample GSM8403746 Runtime Siftome inference GEO:sample:GSM8403746:cf13b0909c66f2202f2a23aced7b5e84abd68087c5761fe9818b9cacb07d53a9 low confidence normal sample_accession: GSM8403746 sample_title: MN-2,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary sample type match: normal
sample_type tumor sample sample GSM8403746 Runtime Siftome inference GEO:sample:GSM8403746:cf13b0909c66f2202f2a23aced7b5e84abd68087c5761fe9818b9cacb07d53a9 low confidence tumor sample_accession: GSM8403746 sample_title: MN-2,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary sample type match: tumor
sample_type normal tissue sample GSM8403747 Runtime Siftome inference GEO:sample:GSM8403747:5908cad837e353123dd557be583d33b0fbcfb4bb9bc6d93d0bc8b44049e350f6 low confidence normal sample_accession: GSM8403747 sample_title: MN-3,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary sample type match: normal
sample_type tumor sample sample GSM8403747 Runtime Siftome inference GEO:sample:GSM8403747:5908cad837e353123dd557be583d33b0fbcfb4bb9bc6d93d0bc8b44049e350f6 low confidence tumor sample_accession: GSM8403747 sample_title: MN-3,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary sample type match: tumor
sample_type tumor sample sample GSM8403748 Runtime Siftome inference GEO:sample:GSM8403748:f9fac435745abedff7873368a2b35d0e584ee52951233b2626500995a5bde656 low confidence tumor sample_accession: GSM8403748 sample_title: MT-1,Tumor,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Tumor tissue MT-1,Tumor,hepatocell... controlled vocabulary controlled vocabulary sample type match: tumor
sample_type tumor sample sample GSM8403749 Runtime Siftome inference GEO:sample:GSM8403749:50a028c1f92f9608d98c0419e6a8e96d15b6136a826e242f8c86e2cbf018579f low confidence tumor sample_accession: GSM8403749 sample_title: MT-2,Tumor,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Tumor tissue MT-2,Tumor,hepatocell... controlled vocabulary controlled vocabulary sample type match: tumor
sample_type tumor sample sample GSM8403750 Runtime Siftome inference GEO:sample:GSM8403750:b56f2806b0f39cc33b0d7f7a649f6f66a7baf1194535eaa5f62525219e86d02e low confidence tumor sample_accession: GSM8403750 sample_title: MT-3,Tumor,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Tumor tissue MT-3,Tumor,hepatocell... controlled vocabulary controlled vocabulary sample type match: tumor
tissue liver dataset GSE272510 Runtime Siftome inference GEO:dataset:GSE272510:760500fbe3fd44e7d03540e5a4fc03207e3856d5d48a0054901b3ce96c2eb61a low confidence liver dataset_accession: GSE272510 dataset_title: Lysine metabolism reprogramming reshapes the immune microenvironment and induces immunotherapy tolerance in liver cancer organism: Ho... controlled vocabulary controlled vocabulary tissue match: liver
tissue liver sample GSM8403745 Runtime Siftome inference GEO:sample:GSM8403745:a2f083756095988b897f3e90d18ad229b19108e2dbf4eff46cc08e9dbf246653 low confidence liver sample_accession: GSM8403745 sample_title: MN-1,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary tissue match: liver
tissue liver sample GSM8403746 Runtime Siftome inference GEO:sample:GSM8403746:cf13b0909c66f2202f2a23aced7b5e84abd68087c5761fe9818b9cacb07d53a9 low confidence liver sample_accession: GSM8403746 sample_title: MN-2,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary tissue match: liver
tissue liver sample GSM8403747 Runtime Siftome inference GEO:sample:GSM8403747:5908cad837e353123dd557be583d33b0fbcfb4bb9bc6d93d0bc8b44049e350f6 low confidence liver sample_accession: GSM8403747 sample_title: MN-3,Normal,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Normal tissue adjacent to tumor M... controlled vocabulary controlled vocabulary tissue match: liver
tissue liver sample GSM8403748 Runtime Siftome inference GEO:sample:GSM8403748:f9fac435745abedff7873368a2b35d0e584ee52951233b2626500995a5bde656 low confidence liver sample_accession: GSM8403748 sample_title: MT-1,Tumor,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Tumor tissue MT-1,Tumor,hepatocell... controlled vocabulary controlled vocabulary tissue match: liver
tissue liver sample GSM8403749 Runtime Siftome inference GEO:sample:GSM8403749:50a028c1f92f9608d98c0419e6a8e96d15b6136a826e242f8c86e2cbf018579f low confidence liver sample_accession: GSM8403749 sample_title: MT-2,Tumor,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Tumor tissue MT-2,Tumor,hepatocell... controlled vocabulary controlled vocabulary tissue match: liver
tissue liver sample GSM8403750 Runtime Siftome inference GEO:sample:GSM8403750:b56f2806b0f39cc33b0d7f7a649f6f66a7baf1194535eaa5f62525219e86d02e low confidence liver sample_accession: GSM8403750 sample_title: MT-3,Tumor,hepatocellular carcinoma source_name: liver characteristics: tissue: liver; tissue type: Tumor tissue MT-3,Tumor,hepatocell... controlled vocabulary controlled vocabulary tissue match: liver

Sample Group Preview

Possible case samples

Samples currently treated as the comparison case group.

3
  • GSM8403748 MT-1,Tumor,hepatocellular carcinoma tumor sample Case marker detected. liver tissue: liver; tissue type: Tumor tissue
  • GSM8403749 MT-2,Tumor,hepatocellular carcinoma tumor sample Case marker detected. liver tissue: liver; tissue type: Tumor tissue
  • GSM8403750 MT-3,Tumor,hepatocellular carcinoma tumor sample Case marker detected. liver tissue: liver; tissue type: Tumor tissue

Possible control samples

Samples currently treated as controls or baseline.

3
  • GSM8403745 MN-1,Normal,hepatocellular carcinoma normal tissue Control marker detected. liver tissue: liver; tissue type: Normal tissue adjacent to tumor
  • GSM8403746 MN-2,Normal,hepatocellular carcinoma normal tissue Control marker detected. liver tissue: liver; tissue type: Normal tissue adjacent to tumor
  • GSM8403747 MN-3,Normal,hepatocellular carcinoma normal tissue Control marker detected. liver tissue: liver; tissue type: Normal tissue adjacent to tumor

Unassigned samples

Samples with no explicit case or control marker.

0

No samples

Excluded samples

Samples excluded from grouping by hard exclusion rules.

0

No samples

Ambiguous samples

Samples that need manual review before trusting grouping.

0

No samples

Metadata Quality Components

Persisted metadata quality

85 pts
Clarity
85%
Weight
100 pts

Sample source clarity: All samples have source metadata and clear GSE/GSM accessions. Group clarity: Rule-based grouping found both case and control samples. Disease clarity: Disease or condition metadata was not normalized. Tissue clarity: Tissue metadata normalized. Treatment clarity: No unclear treatment split detected in the sample metadata. Replicate clarity: No pooled sample or technical replicate flags detected. Data availability clarity: Dataset-level processed or raw data availability is explicit.

Detected Sample Groups

normal tissue

3 samples
  • GSM8403745 MN-1,Normal,hepatocellular carcinoma liver tissue: liver; tissue type: Normal tissue adjacent to tumor
  • GSM8403746 MN-2,Normal,hepatocellular carcinoma liver tissue: liver; tissue type: Normal tissue adjacent to tumor
  • GSM8403747 MN-3,Normal,hepatocellular carcinoma liver tissue: liver; tissue type: Normal tissue adjacent to tumor

tumor sample

3 samples
  • GSM8403748 MT-1,Tumor,hepatocellular carcinoma liver tissue: liver; tissue type: Tumor tissue
  • GSM8403749 MT-2,Tumor,hepatocellular carcinoma liver tissue: liver; tissue type: Tumor tissue
  • GSM8403750 MT-3,Tumor,hepatocellular carcinoma liver tissue: liver; tissue type: Tumor tissue

Score Breakdown

60%

relevance

  • Organism normalized.
  • Assay type normalized.
  • Tissue metadata normalized.
0%

comparison suitability

  • Tumor and normal sample groups detected.
  • No excluded sample type flags detected.
  • Tumor/normal design boosted for colorectal tumor-vs-normal tissue triage.
  • Patient tissue or biopsy specimens boosted for tissue comparison triage.
  • Non-colorectal cancer context downgraded for colorectal tumor-vs-normal tissue ranking.
85%

metadata quality

  • Sample source clarity: All samples have source metadata and clear GSE/GSM accessions.
  • Group clarity: Rule-based grouping found both case and control samples.
  • Disease clarity: Disease or condition metadata was not normalized.
  • Tissue clarity: Tissue metadata normalized.
  • Treatment clarity: No unclear treatment split detected in the sample metadata.
  • Replicate clarity: No pooled sample or technical replicate flags detected.
  • Data availability clarity: Dataset-level processed or raw data availability is explicit.
100%

data availability

  • Processed data available.
  • Raw data available.
34%

overall

  • Weighted score: 30% relevance, 30% comparison suitability, 25% metadata quality, 15% data availability.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because fewer than ten samples limit cohort confidence.
  • Overall score capped because tumor/normal grouping is from a non-colorectal cancer context.

Sample Links

6 samples

Review Audit Trail

0 decisions

No review decisions have been stored for this dataset.